What we do
We read each program’s own pages and record what it charges, who prescribes, which pharmacy fills and what it says about FDA status, with the date we read it. We pair that with what the clinical trials and FDA actually say, so you can judge a program on evidence rather than marketing. Our clinical library covers the STEP, SURMOUNT, SELECT and FLOW trials, and our peptide profiles carry dated FDA compounding-status notices.
Dr. Parmis — Research and editing
Dr. Parmis is a medical researcher (Western University of Health Sciences) who leads research and writing for American Telehealth Review, including the first-party price reads and the v4.1 methodology.
Dr. Jonathan Snipes, MD — Medical reviewer
Dr. Snipes reviews pages for medical accuracy. NPI 1821250077.
Kim Callender, NP (FNP-BC) — Medical reviewer
Kim Callender is a board-certified family nurse practitioner (FNP-BC) who reviews pages for medical accuracy. NPI 1144661760.
What we cover
- Telehealth programs that prescribe brand GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, the Wegovy pill, Foundayo) and compounded semaglutide and tirzepatide.
- Peptide and hormone clinics, with dated FDA status for each peptide.
- Clinical trials, FDA actions and coverage changes that affect cash-pay patients.
What we are not
- Not a healthcare provider, pharmacy or insurer. We do not prescribe.
- Not affiliated with FDA, Novo Nordisk, Eli Lilly or any government agency.
- Not medical advice: talk with a licensed clinician before starting or changing treatment.
Contact and corrections
Email americantelehealthreview@gmail.com. See our editorial standards and corrections log.